Shots:

• The data contains HAVEN 3 (N=152) study evaluating Hemlibra (emicizumab) prophylaxis vs no prophylaxis with patients aged ≥12 yrs
• HAVEN 3 results: (reduction in treated bleeds 96%/qw- 97%/q2w); (zero treated bleeds 55.6%/qw- 60%q2w); (three or fewer treated bleeds 91.7%qw- 94.3%q2w); (reduction in treated target-joint bleeds 95%)
• The US granted Hemlibra BT&PR designations for people with haemophilia A without factor VIII- with expected approval by 4 Oct-2018

Ref: Roche | Image: Roche